Citation: Rt. Mccormack et Pc. Southwick, Informed consent in clinical trials of in vitro diagnostic devices: Perspectives from the FDA and manufacturers - A perspective from manufacturers, CLIN CHEM, 47(10), 2001, pp. 1755-1757
Authors:
Catalona, WJ
Southwick, PC
Slawin, KM
Partin, AW
Brawer, MK
Flanigan, RC
Patel, A
Richie, JP
Walsh, PC
Scardino, PT
Lange, PH
Gasior, GH
Loveland, KG
Bray, KR
Citation: Wj. Catalona et al., Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging, UROLOGY, 56(2), 2000, pp. 255-260
Authors:
Catalona, WJ
Partin, AW
Slawin, KM
Naughton, CK
Brawer, MK
Flanigan, RC
Richie, JP
Patel, A
Walsh, PC
Scardino, PT
Lange, PH
deKernion, JB
Southwick, PC
Loveland, KG
Parson, RE
Gasior, GH
Citation: Wj. Catalona et al., Percentage of free PSA in black versus white men for detection and stagingof prostate cancer: A prospective multicenter clinical trial, UROLOGY, 55(3), 2000, pp. 372-376
Authors:
Southwick, PC
Catalona, WJ
Partin, AW
Slawin, KM
Brawer, MK
Flanigan, RC
Patel, A
Richie, JP
Walsh, PC
Scardino, PT
Lange, PH
Gasior, GH
Parson, RE
Loveland, KG
Citation: Pc. Southwick et al., Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: A prospective multicenter clinical trial, J UROL, 162(4), 1999, pp. 1346-1351
Authors:
Chan, DW
Kelley, CA
Ratliff, TL
D'Agostino, D
Ritchey, J
Lamb, DJ
Beck, J
Lott, N
Wener, MH
Daum, P
Henkin, RE
Kaske, DN
Golightly, DW
McBride, J
Layco, G
Ota, MK
Tanasijevic, MJ
Grudzien, C
Woodrum, DL
Bray, KR
Southwick, PC
Gasior, GH
Loveland, KG
Citation: Dw. Chan et al., Analytical and clinical performance characteristics of Hybritech's Tandem-R free PSA assay during a large multicenter clinical trial to determine theclinical utility of percentage of free prostate-specific antigen, CLIN CHEM, 45(10), 1999, pp. 1863-1865